Review article

Diagnostic approach to persistent hepatic encephalopathy

Macías-Rodríguez RU, Torre A.

Abstract

Introduction: Hepatic encephalopathy (HE) is a complication of cirrhosis manifested by neuropsychiatric and neuromuscular changes with impact on quality of life. Clinical picture ranges from normal physical exam to stupor and coma. In persistent HE, patient never becomes free of HE.

Objective: To review medical literature searching for evidence concerning persistent HE and non-classical factors involved in its development.

Methods: We identified articles by searching PubMed (1966 to January 2011), EMBASE (1980 to January 2011) and Pubgle. Relevant articles with the terms persistent AND hepatic AND encephalopathy were selected. Precipitating factors of this clinical picture were recorded.

Results: Many factors lead to HE and contribute to its persistence. The most common are gastrointestinal

Keywords: Persistent hepatic encephalopathy, cirrhosis, porto-systemic bypass, small intestinal bacterial overgrowth, anemia, Mexico.

Resumen

Introducción: La encefalopatía hepática (EH) es una complicación de la cirrosis y consiste en cambios neuropsiquiátricos y neuromusculares con impacto en la calidad de vida del paciente. La presentación clínica va desde una exploración física normal (grado 0), hasta el estupor y coma (grado IV). Cuando el paciente tiene alteraciones neuropsiquiátricas de forma continua, sin llegar a un nivel normal, se le llama EH persistente.

Objetivo: Revisar los factores que inician y perpetúan la EH persistente, así como sus implicaciones fisiopatológicas.

Métodos: Se realizó una búsqueda en PubMed (1966 a enero 2011), EMBASE (1980 a enero 2011) and Pubgle con los términos persistent AND hepatic AND encephalopathy. Se seleccionaron los estudios sobre la encefalopatía hepática persistente y los factores desencadenantes.

Palabras clave: Encefalopatía hepática persistente, cirrosis, corto-circuitos porto-sistémicos, sobrepoblación bacteriana, anemia, México.

Correspondence author: Aldo Torre. Vasco de Quiroga 15, Col. Sección XVI, Delegación Tlalpan, México D.F. C.P. 14000.
E-mail address: detoal@yahoo.com.

Received July 26th, 2011; accepted September 20th, 2011.
Introduction

Hepatic encephalopathy (HE) is a neurological syndrome characterized by neuropsychiatric changes coupled to the presence of neuromuscular alterations resulting from severe progressive hepatic insufficiency, after exclusion of other known brain disease.\(^1\)

Symptoms of HE include attention deficit, changes in sleep patterns and a lack of muscular coordination that can progress to stupor and coma.\(^2\) HE is classified into three distinct types: Type A, which occurs in patients with acute hepatic insufficiency; Type B, which arises in patients with portosystemic bypass; and Type C, when HE occurs in patients with cirrhosis.\(^1\) In addition, Type C HE is further subdivided into three subtypes:

A. Episodic: This subtype results from precipitating factors or can occur spontaneously in the absence of such factors. Therefore, the presence of gastrointestinal hemorrhage, uremia, infections, constipation, dehydration, hyponatremia, hypokalemia, dietary transgressions, the use of diuretics, an increase in renal ammonium load, and the use of psychotropic drugs, among other factors, must be excluded (Table 1). When one or more episodes of HE occur within a single year, it is referred to as recurrent hepatic encephalopathy.

B. Persistent: This subtype includes cognitive deficits that negatively affect quality of life. The non-cognitive abnormalities, such as extrapyramidal disorders or sleep disturbances require separate analysis. This type of encephalopathy is subdivided, according to West Heaven classification, into mild HE (grade I HE) and severe (grades II to IV HE). Treatment-dependent persistent hepatic encephalopathy is a subgroup in which symptoms reappear quickly when treatment is suspended. The difference between persistent and episodic HE is that in the former, patients never become free of HE and in the latter patients remain asymptomatic between HE episodes (Figure 1).\(^3^,^4\)

C. Minimal: Minimal HE (MHE) is identified when poor performance is observed in neuropsychological tests (e.g., number connection test or trail-making test/ digit symbol test), but the patient does not show obvious clinical changes. It is important to identify deterioration in cognitive function in patients with minimal HE, because it has been reported that these patients are at high risk for car accidents and possibly occupational accidents when handling machinery.\(^5^,^6\) The psychometric hepatic encephalopathy score (PHES), is a battery of neuropsychological tests, and recently has been validated for Mexican population. This set of tests helps in the diagnosis of MHE.\(^7\)
Approximately 28% of cirrhotic patients develop HE during the course of the disease and subclinical neuropsychiatric changes have been identified in up to 84% of patients. This high prevalence coupled with the increasing incidence of chronic hepatic diseases (e.g., non-alcoholic steatohepatitis, hepatocarcinoma, etc.) and the longer survival associated with most effective treatment suggest that HE may become a highly frequent problem in clinical practice. In Mexico, an analysis of the trend in hepatic diseases has predicted that by the year 2050 there will be about 1.5 million chronic liver disease cases that will be susceptible to HE. Furthermore, it is known that cirrhosis primarily affects economically active population (35 to 55 years old), which may result in a significant economic burden. An accurate assessment of the pathophysiological basis of HE will facilitate better preventive and therapeutic approaches and will better assist patients with persistent HE, a problem commonly encountered in daily clinical practice. Therefore our aim was to review medical literature searching for evidence concerning persistent HE and precipitating factors in addition to classical ones.

### Table 1. Factors precipitating hepatic encephalopathy.

<table>
<thead>
<tr>
<th>Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic encephalopathy drug non-compliance (e.g. Disaccharides, L-Ornithine L-Aspartate)</td>
</tr>
<tr>
<td>Water-electrolyte imbalance</td>
</tr>
<tr>
<td>Hypo/hyperkalemia</td>
</tr>
<tr>
<td>Systemic alkalosis</td>
</tr>
<tr>
<td>Hyponatremia</td>
</tr>
<tr>
<td>Dehydration</td>
</tr>
<tr>
<td>Disaccharides induced diarrhea</td>
</tr>
<tr>
<td>Diuretic use</td>
</tr>
<tr>
<td>Low digestion</td>
</tr>
<tr>
<td>Low blood pressure</td>
</tr>
<tr>
<td>Metabolic abnormalities</td>
</tr>
<tr>
<td>Infection</td>
</tr>
<tr>
<td>Spontaneous bacterial peritonitis (SBP)</td>
</tr>
<tr>
<td>Non-SBP infections (e.g. cellulitis, periodontitis, pneumonia)</td>
</tr>
<tr>
<td>Constipation</td>
</tr>
<tr>
<td>Gastrointestinal bleeding (acute)</td>
</tr>
<tr>
<td>Upper variceal bleeding</td>
</tr>
<tr>
<td>Blood transfusion</td>
</tr>
<tr>
<td>Hyperzoemia (renal failure)</td>
</tr>
<tr>
<td>Anemia</td>
</tr>
<tr>
<td>Poor dietary intake (iron, B12 vitamin, folates)</td>
</tr>
<tr>
<td>Chronic gastrointestinal bleeding (portal hypertensive gastropathy)</td>
</tr>
<tr>
<td>Psychotropic use (benzodiazepines)</td>
</tr>
<tr>
<td>Porto-systemic shunts</td>
</tr>
<tr>
<td>Transjugular intrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>Surgical Progressive hepatic damage</td>
</tr>
<tr>
<td>Neoplasia</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>Any other</td>
</tr>
<tr>
<td>Excessive dietary protein load</td>
</tr>
<tr>
<td>Small Intestinal Bacterial Overgrowth (SIBO)</td>
</tr>
<tr>
<td><em>Helicobacter pylori</em> infection (ammonia overproduction by urease)</td>
</tr>
</tbody>
</table>

### Figure 1. Relationships between hepatic encephalopathy (HE) grades along time in persistent HE. These patients never become free of HE.

We identified the articles by searching PubMed (1966 to January 2011), EMBASE (1980 to January 2011) and Pubgle. Relevant articles with the terms persistent AND hepatic AND encephalopathy were selected. We extracted data on factors precipitating and perpetuating hepatic encephalopathy.

### Epidemiology of Type C chronic HE

There are few studies that have determined the prevalence of HE by examining an established cohort. Recently Romero-Gómez and collaborators in a cohort with 25% prevalence of minimal hepatic encephalopathy, reported an overt hepatic encephalopathy incidence of 18% to 44% at 29 months follow up, and linked to genetic factors. HE was reported in 13% of patients who have had a first episode of ascites and in more than 69% of
patients hospitalized for variceal bleeding.\textsuperscript{13} Preva-
ience of minimal hepatic encephalopathy (MHE) de-
ends on the methods used for its diagnosis, if
psychometric tests and electroencephalograms are
used, approximately 15\% to 50\% and 20\%, are de-
tected respectively.\textsuperscript{14,17}

The mortality rate of each HE episode depends
on the patient’s degree of hepatic insufficiency
and the severity of the episode. Interestingly, it
has been reported that 42\% and 23\% of patients
at 1 and 3 years, respectively, survive the first HE
episode.\textsuperscript{18}

Risk factors for the development of HE have
not been completely identified. Portal hy-
pertension with esophageal varices\textsuperscript{19} and advanced hep-
tic disease (Child C or ascites)\textsuperscript{18} have been identi-
ced as independent predictors of HE development.
When transjugular intrahepatic portosystemic shunt
(TIPS) is placed, older age (over 55 years old), previous history of HE, low hepatic pres-
ure gradient, and a Child-Pugh score more than 11
are all considered independent predictors of the
development of HE after shunt placement.\textsuperscript{20-23} In
patients with persistent or recurrent HE, presen-
ce of spontaneous portosystemic shunts must be
sought.\textsuperscript{24}

Finally, the underlying causes of HE are iden-
tified in up to 97\% of cases when HE is episodic,
while it is only identified in 70\% of the cases when
HE is recurrent. Multiple precipitating factors of HE
must be sought (Table 1).\textsuperscript{25,26}

\textbf{Approach to persistent hepatic encephalopathy}

Considering that persistent HE causes cognitive
deficit with impact on quality of life, in addition
to the usual treatment, there will always be a need to
thoroughly investigate the causes that may result
in persistent symptoms based on the following evi-
dence:

\textbf{A. Spontaneous Portosystemic Shunts:} The use
of transjugular intrahepatic portosystemic shunt
(TIPS) and its relationship to HE development has
been clearly established in patients with cirrhosis.
Although the presence of a shunt would classify
the disease as Type B HE, its persistence may per-
petuate the chronic nature of HE. Patients possess-
sing these shunts may present neuropsychological
abnormalities and high levels of ammonium even
in the absence of severe hepatic insufficiency.\textsuperscript{27} In
patients with cirrhosis, the high incidence of HE
after portal derivative surgery\textsuperscript{28} and the presence
of radiological portocaval shunts\textsuperscript{29} has been con-
formed; thus a relationship between the diameter of
the anastomosis and the incidence of HE has been
reported.\textsuperscript{30} Recently, Riggio and collaborators\textsuperscript{34}
performed a case-control study founding that
spontaneous shunts can perpetuate the chronicity
of HE. In the aforementioned study, the suspec-
ted effect of spontaneous shunts was confirmed by
conducting computerized tomography and three-
dimensional reconstructions of the portal system
and notably demonstrated that their presence is
not directly related to the degree of hepatic insuffi-
cency. However, CT showed preservation of the
portal vein diameters in this group of patients, but
increase in the diameters of the splenic and left
renal veins, indicating that most of the flow is de-
erved from the superior mesenteric vein and not
from the portal vein, resulting in a shunt similar
to surgical spleno-renal anastomosis.

In patients with changes in their neuropsycho-
metric tests, brain spectroscopy was performed
and revealed glutamine-glutamate peaks with a
concurrent decrease in myo-inositol levels. These
results were notably similar to the peaks found in
patients with HE and cirrhosis who lacked the pre-
ence of shunts. Thus, it is thought that a sponta-
neneous shunt can lead to HE even in the absence
of severe hepatic damage.

Once identified, the shunts are treated with
interventional radiology to reduce the shunt dia-
eter with placement of coils or embolization,
which results in a significant reduction of neuro-
logical symptoms. Rarely, there is a transient in-
crease in portal pressure after the procedure that
can result in ascites and esophageal varices, such
problems must be treated under the guidelines al-
ready established.

\textbf{B. Use of diuretics:} In patients with cirrhosis,
dehydration induced by the administration of diu-
retics is a common cause of HE, which is influen-
ced by changes in volume. The mechanism by
which HE is induced is not fully understood in this
case, however, Jalan and collaborators\textsuperscript{31} recently
demonstrated that plasma expansion significantly
reduces the concentration of plasma ammoni-
ium, probably through an increased excretion of
ammonium through the urine. This reduction in
ammonium levels was reported in patients treated
with albumin and was accompanied by a de-
crease in oxidative stress, which implies that the
oxidative stress and ammonium may be linked to the pathogenesis of HE induced by diuretics, suggesting a possible role of albumin infusion as an effective treatment regimen.

It is probable that changes in ammonium homeostasis, secondary to volume expansion, increase the luminal flow by improving renal perfusion, in the same way, diuretics are known to inhibit the transporters involved in the excretion of ammonium. Alternatively, this change in ammonium levels can also be achieved through a decrease in renal ammoniagenesis facilitated by a reduction in the production of angiotensin II, which is an important modulator of ammonium synthesis in the proximal tubule. The hypothesis proposed in the afore mentioned study by Jalan is supported by a direct correlation between the decrease in levels of angiotensin II and plasma ammonium, with results in an increase in the excretion of ammonium through urine, such as those patients with hepatorenal syndrome.

Another important observation is that improvement in HE was largely achieved in patients who were treated with albumin when compared to patients treated with synthetic expanders (Gelofusine) despite the latter’s ability to reduce the ammonium plasma concentrations. This implies that the mechanism by which albumin improves HE involves something other than an effect on volume expansion. It should be noted that albumin is a 66 kDa protein and constitutes 50% of the plasma protein content in healthy individuals. Among its numerous functions, albumin acts in the fixation of various substances such as fatty acids, bilirubins, bile salts, amino acids, and nitric oxide, reducing most of the sulfhydryl groups present at the extracellular level. As such, albumin can limit the production of reactive species and hence production of free radicals, improves the redox balance, and reduces oxidative stress. In the study performed by Jalan, this hypothesis was supported by the observed reduction in the levels of malondialdehyde in the group of patients who were administered albumin, a phenomenon that was not observed in the group administered synthetic expanders, suggesting that oxidative stress may be involved. This hypothesis was validated by the reduction in malondialdehyde levels and by evidence that oxidative stress is part of the physiopathology of HE, possibly via mitochondrial damage, involving the oxidation of membrane phospholipids and enzymes that facilitate energy metabolism. In fact, oxidative stress is a recently studied pathway that includes nitric oxide imbalance, endothelial dysfunction, messenger RNA oxidation, and down regulation of antioxidant pathways such as superoxide dismutase, catalase and glutathione peroxidase.

C. Renal insufficiency: The cognitive compromise is a common problem observed in patients with cirrhosis, and it has multifactorial etiologic factors, considering that ammonium has a central role in its pathophysiology. Renal function, in addition, has proved to be an important factor in ammonium metabolism, so its association with cognitive changes may be related. Recently, Kalaitzakis and collaborators studied 128 cirrhotic patients and evaluated their cognitive dysfunction by performing neuropsychological tests. Of the 128 patients enrolled in the study, 41 (32%) demonstrated cognitive changes, and of these, 16 (13%) had renal insufficiency. When the group with renal insufficiency was compared to those individuals without renal insufficiency, the presence of cognitive changes was 69% vs. 31% (p = 0.001), respectively. Without inferring the etiology or severity of cirrhosis from these reported differences, we conclude that renal dysfunction in cirrhosis patients is implicated in the physiopathology of HE.

D. Anemia: It is well known that for many diseases, nutritional changes and metabolic or hormonal changes can alter cognitive function. Anemia caused by cerebral hypoxia has been shown to have a strong influence on cognition. However, the most well characterized group is perhaps those patients with chronic renal insufficiency where the concept of neuroprotection and/or neuroregeneration was established when the anemia is treated, specifically with erythropoietin. This treatment has not been studied in patients with hepatic damage, but understanding that erythropoietin acts as an antiapoptotic, anti-inflammatory, antioxidant, neurotrophic and angiogenic factor, may invariably alter the therapeutic plan by modify the degree of oxidative stress via an alternative pathway in the pathophysiology of hepatic encephalopathy (Figure 2).

E. Hydroelectrolytic changes: It has been shown that in patients with advanced cirrhosis there is a reduction in the concentration of several brain osmolyltes, particularly myo-inositol. Dilutional hyponatremia significantly modifies the balance
between these osmolytes, particularly glutamines and myo-inositol through an osmoregulatory mechanism to prevent the increase in the content of brain water, which can contribute to astrocyte dysfunction through the occurrence of HE (Figure 2). Restuccia and collaborators reported a decrease in myo-inositol levels and an increase in glutamine levels using spectroscopy and magnetic resonance imaging, indicating an increase in glutamine in relation to ammonium levels. In addition, the presence of low-grade cerebral edema was showed by measuring the magnetization transfer ratio (MTR), a magnetic resonance imaging modality that measures brain water content in cirrhotic compared with non-cirrhotic patients.

**F. Chronic gastrointestinal bleeding:** The presence of acute intestinal bleeding is widely recognized in patients with HE, but recently the role of chronic bleeding has also been established in patients with HE. Romero-Gómez and collaborators observed that with an oral glutamine load (mimicking acute gastrointestinal bleeding and thus high ammonia load), patients had a higher risk of exhibiting HE, which has a significant impact on patient survival. Portal hypertensive gastropathy is found in 9% to 80% of cirrhotic patients, and is a cause of chronic gastrointestinal bleeding. Treatment consists in ethanol, aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) avoidance, beta-blockers therapy, TIPS or liver transplantation.

**G. Other factors perpetuating HE:** Helicobacter pylori infection might contribute to persistent cognitive impairment in cirrhotic patients by increasing ammonia levels through urease activity. In this context, treatment of infected cirrhotic patients can help to diminish ammonia blood levels.

The main source of ammonia derives from small bowel glutaminase activity and intestinal bacterium (85% of total body production). In a study of 34 cirrhotic patients, it was found HE in 85% of patients and 71% had a positive breath test for small intestinal bacterial overgrowth (SIBO). Prevalence of SIBO was 50%, 61% and 100% in patients without EH, grade I-II EH and grade III-IV EH, respectively ($p = 0.04$). This must be considered as a perpetuating factor and must be sought and treated when HE persists.

**Treatment of persistent HE**

Management of this entity must focus on search of all causes above mentioned, and treat as appropriate. Therapeutic options for HE are directed towards the reduction of ammonia production, increase in fixation and/or excretion of ammonia, direct neurological action and modifying porto-systemic collaterals. Therapies such as non-absorbable disaccharides (basically lactulose), antibiotics (rifaximin, neomycin, etc.), L-ornithine-L-aspartate, acetylcarnitine and acarbose may help to properly manage this clinical entity. Orthotopic liver transplantation constitutes the best therapy.

**Conclusions**

Persistent HE should always obligate to search for some factors that will be responsible for triggering and perpetuating this condition (Table 1). Several events can lead to HE, including oxidative stress, mitochondrial damage, persistent hypoxia, and changes in brain osmolarity resulting in astrocyte dysfunction with apparent HE (Figure 3). Understanding of pathophysiological issues, such those mentioned above, help to establish the best diagnostic and therapeutic approach in HE. Other non-classic factors may be involved in HE perpetuation, so anemia, spontaneous porto-systemic shunts, H. pylori infection, hydroelectrolytic imbalance and diuretic use must be excluded in these patients.

**Acknowledgments**

To the CONACYT (Consejo Nacional de Ciencia y Tecnología).
Figure 3. Multiple factors affect the astrocyte, such as diuretic use, anemia and bacterial infections (systemic inflammatory response syndrome, SIRS) that give rise to hyponatremia and hyperammonemia. This in turn causes osmolyte reduction and eventually astrocyte edema. This edema is the cause of neuronal dysfunction that originates the clinical picture of hepatic encephalopathy.

References